Takeda Looks To Counter R&D Setbacks With Ramped Up Sales Efforts

TOKYO - Having suffered considerable setbacks in launching its core pipeline drugs, Takeda Pharmaceutical will focus on expanding sales growth of existing products, including the gastronomic treatment Kapidex (dexlansoprazole) and gout medication Uloric (febuxostat) that were approved by U.S. FDA in early 2009, the company said in its earnings report and related documents May 11